This Solicitation opportunity from Government of Canada was posted on September 15, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Request For Proposal (RFP) for Pharmacological testing of novel opioids, stimulants, and synthetic cannabinoids.

Closed

1000273405International

Submission Closed09/25/2026, 05:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541715

New

DIBBS

First Article Test (FAT) SpecialistThis subcontract opportunity is for a First Article Test Specialist to perform prototype manufacture and validation testing for prime contractors supporting DLA Weapons Support combat vehicle projects. The selected provider will produce one initial unit and conduct rigorous testing using flow, pressure, and integrity measurement equipment to ensure strict adherence to technical drawings 19207 8338562 and 19207 12342887. The final deliverables for this project include one fully tested unit and a comprehensive test report. The contract is a total small business set-aside under NAICS code 541715, with performance taking place in Barstow, California. Compliance requirements are stringent, necessitating US/Canada Joint Certification Program approval and adherence to DFARS 252.204-7012 standards. Interested parties must respond by November 2, 2026.

DLA WEAPONS SUPPORT LSO COMBAT VEHICLES AND ARMAMENT

POSTED

DEADLINE

Notice of Participation of the National Institute of Nursing Research (NINR) in PAR-27-077, "NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)"

Solicitation # NOT-NR-27-001

The National Institute of Nursing Research has officially joined the NIH Science Education Partnership Award funding opportunity, identified as PAR-27-077. This participation is effective for all applications submitted on or after January 25, 2027. The program specifically utilizes the R25 mechanism and does not allow for clinical trials. Under this updated notice, the National Institute of Nursing Research joins a broad group of participating organizations, including the National Institute of General Medical Sciences and the National Institute on Aging, among others. All submitted applications must align with the mission of the involved Institutes or Centers. While the National Institute of Nursing Research now serves as a scientific and financial contact for this opportunity, all other original terms and conditions of the announcement remain unchanged.

National Institute Of Nursing Research

POSTED

DEADLINE

Notice of NEI Participation in PAR-27-077 NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)

Solicitation # NOT-EY-27-004

The National Eye Institute is announcing its participation in the NIH Science Education Partnership Award (SEPA), identified as PAR-27-077. This participation is effective for all applications with due dates on or after January 25, 2027. The funding opportunity is designated as an R25 grant, and clinical trials are not allowed. The NEI joins a broad group of participating NIH organizations, including the National Institute of General Medical Sciences and the National Institute on Aging, among others. All applications must align with the mission of the participating Institutes or Centers. The update specifically adds the National Eye Institute to the list of participating organizations and provides the corresponding scientific and financial grants management contacts for the agency.

National Eye Institute

POSTED

DEADLINE

Autonomous GNC (Guidance, Navigation, and Control) SoftwareThis subcontract involves the development and integration of autonomous Guidance, Navigation, and Control (GNC) software for prime contractors supporting DARPA Cattle Run projects. The scope of work includes creating algorithms for autonomous navigation, establishing vehicle control laws for renewable propulsion, and managing sensor integration through the use of GNC simulation tools and flight software environments. The final deliverables consist of a validated GNC software suite and corresponding flight code. Eligible candidates must hold U.S. Citizenship and maintain CMMC Level 2 or NIST SP 800-171 Rev 2 compliance. This opportunity falls under NAICS code 541715 and is associated with the Defense Advanced Research Projects Agency within the Department of Defense. The response deadline for this requirement is November 4, 2026.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Histopathology Consultation ServicesThis subcontract for Histopathology Consultation Services supports prime contractors on Department of Veterans Affairs research projects. The selected provider will deliver expert intellectual consultation focusing on study design and methodologic approaches for the histopathologic evaluation of tissues, specifically regarding coronary and leptomeningeal research. Key deliverables include the development of methodologic approaches, the review of tissue analysis protocols, and the provision of consultation reports and study design frameworks. Qualified candidates must hold professional medical and pathology licensure to perform these specialized services. The opportunity is associated with NAICS code 541715 and is managed through the Department of Veterans Affairs Network Contract Office 22. Interested parties should note the response deadline of October 29, 2026.

262-NETWORK Contract Office 22 (36C262)

POSTED

DEADLINE

TESS Engagement System IntegrationThe TESS Engagement System Integration is a subcontract managed by the Department of Defense under the agency W6QK Acc-Apg-Orlando. The project focuses on integrating the interface between Unmanned Aircraft Systems and Tactical Engagement Simulation System hardware for prime contractors supporting Army PdM TTS projects. This technical effort involves implementing the TRACR II ICD Message ID 0x2A11 to report engagement events from god guns or TESS player units and mapping casualty results to specific ICD enum values. The primary objective is to deliver a validated engagement reporting loop from TESS to UAS, which requires the use of TESS hardware and player units. The work is performed in Orlando, Florida, under NAICS code 541715. The solicitation was posted on October 22, 2026, with a response deadline of November 22, 2026.

POSTED

DEADLINE

Synthetic Data Generation and ModelingThis subcontract for Synthetic Data Generation and Modeling supports prime contractors on projects for the Navy NSWC Port Hueneme under the Department of Defense. The primary objective is the provision of synthetic data generation services to simulate equipment degradation and the creation of anomalous condition datasets specifically designed for model testing and validation. The scope of work requires the delivery of validated synthetic datasets along with the tools used for their generation. This effort falls under NAICS code 541715, with a response deadline set for November 5, 2026.

POSTED

DEADLINE

Instrumentation and Procedure Scientific ConsultationThis subcontract, titled Instrumentation and Procedure Scientific Consultation, provides professional scientific and technical advisory services to prime contractors supporting NIH/NCI cancer diagnostic projects. The scope of work focuses on delivering expert guidance from scientists and engineers regarding the utilization of Roche Ventana Benchmark ULTRA units, specifically focusing on instrumentation optimization and the development of procedures for immunohistochemistry and in situ hybridization. Managed under the National Institutes of Health within the Department of Health and Human Services, the contract is categorized under NAICS code 541715. The place of performance is located in Bethesda, Maryland. The solicitation was posted on October 22, 2026, with a response deadline of October 28, 2026.

National Institutes Of Health Olao

POSTED

DEADLINE

Tunable Protein Purification System R&DThe Tunable Protein Purification System R&D is a subcontract under the Defense Advanced Research Projects Agency within the Department of Defense. The project focuses on core research and engineering to design and build a tunable purification platform intended for prime contractors on DARPA biochemical projects. The primary objective is to develop mechanisms that target proteins based on physicochemical heterogeneities, shifting away from traditional affinity methods through the use of novel membranes, microfluidics, or advanced chromatography. The successful contractor must adhere to DARPA IV&V protocols to ensure rigorous validation and verification. Final deliverables include a fully functional, tunable purification platform along with comprehensive process documentation. This effort is categorized under NAICS code 541715, with a response deadline set for November 9, 2026.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

FY 26 Broad Agency Announcement (BAA) - Federal Railroad Administration

Solicitation # 693JJ626R000001

The Federal Railroad Administration Office of Research, Development, and Technology is soliciting applied research projects through the FY 2026 Broad Agency Announcement 693JJ626R000001 to support rail safety and efficiency. The scope of work focuses on three primary research divisions: Track, Rolling Stock and Equipment, and Train Control and Communications. Interested innovators and subject matter experts must submit concept papers for review, which, if approved, allow for the submission of a full proposal. The solicitation operates on a rolling basis with a final deadline of September 30, 2027, though specific research topics are periodically removed via amendments as they become unavailable. Awards may be structured as firm-fixed-price or cost-reimbursable contracts, with technical merit serving as the most significant evaluation factor, followed by cost or price and past performance. Selected contractors are required to provide detailed statements of work, annual research results or technical reports, and periodic self-assessments. Contract administration is managed through the DELPHI system for electronic invoicing, and all deliverables must be submitted 30 days prior to the end of the performance period. Compliance requirements include adherence to FAR clauses regarding telecommunications equipment, patent rights reporting via DD Form 882, and strict reporting templates for monthly and quarterly progress.

Federal Railroad Administration

POSTED

DEADLINE

HERMES BAA CALL: Rotating Detonation Rocket Engine-Combined Cycle (RDRE-CC) Flight Demonstration

Solicitation # FA9300-20-S-0001-CALL-RDRE-CC

The Air Force Research Laboratory Rocket Propulsion Division is issuing a two-step call for proposals under the HERMES Broad Agency Announcement to mature Rotating Detonation Rocket Engine-Combined Cycle propulsion systems from TRL 3 to TRL 6. The objective is to conduct a ground-launched flight demonstration to validate operational viability for High-Speed Affordable Mass Munitions. The anticipated period of performance is 36 to 48 months, with the process beginning with the submission of a ten-page white paper and an optional five-page technical appendix by November 16, 2026. Recent amendments have introduced revised technical questions and answers, specifically adding clarification on air-launched flight demonstrations. Additionally, the government will utilize a non-government advisor from Sierra Lobo, Inc. to provide technical subject matter expertise during the evaluation of white papers and proposals. This advisor will act in a strictly advisory capacity and is bound by non-disclosure agreements, though prospective offerors may submit documented objections to the disclosure of their proprietary data within three business days of the notice. Access to controlled technical documents requires a valid CAGE code and JCP certification via SAM.gov.

POSTED

DEADLINE

Protein Palace Proposers Day

Solicitation # DARPA-SN-27-01

The Defense Advanced Research Projects Agency (DARPA) Multi X Office is hosting an in-person Proposers Day for the Protein Palace program on November 17, 2026, at the Executive Conference Center in Arlington, Virginia. This event is issued under Special Notice DARPA-SN-27-01 for information and program planning purposes and does not constitute a formal solicitation. The Protein Palace program seeks to develop agile, tunable protein purification methods that move beyond current state-of-the-art physicochemical methods to separate target proteins at high purity and yield. The program is structured in two phases: a 24-month first phase focusing on specificity and generalizability by separating eight different proteins, followed by an 18-month second phase focusing on scalability and throughput using two difficult-to-purify proteins. Interested parties must register by November 9, 2026, at 4:00 p.m. ET, submitting required documentation such as DARPA Form 104, Form 60 for permanent residents or foreign nationals, or a Foreign Visit Request for official foreign government personnel. The event will be held at the unclassified level, and attendees must provide government-issued photo identification. While a formal solicitation is expected to be released on sam.gov prior to the event, any proposals submitted in response to this special notice will be disregarded. Technical inquiries are directed to Dr. Huanan Zhang, the MXO Program Manager.

Defense Advanced Research Projects Agcy

POSTED

1 day ago

DEADLINE

in 17 days

AI Contract Overview

Health Canada is seeking proposals for the in vitro pharmacological testing of novel psychoactive substances to support regulatory science decisions and risk assessments under the Controlled Drugs and Substances Act. The procurement is divided into three separate streams: Stream 1 focuses on emerging opioids at the mu opioid receptor, Stream 2 covers novel synthetic cannabinoids at CB1 and CB2 receptors, and Stream 3 involves stimulant compounds, such as synthetic cathinones. Bidders may apply for one, two, or all three streams, with up to three contracts potentially awarded. The work includes acquiring reference standards, obtaining necessary controlled substance licenses, conducting experiments with statistical analysis, and delivering comprehensive reports. The project follows a phased timeline, with licensing and validation typically completed within eight months of award and final reports due approximately 17.5 months after award. All laboratory work must be conducted at the contractor's facility using validated methodologies and industry-recognized quality assurance procedures. Technical staff must meet specific academic credentials, including MSc or post-doctoral levels for complex analyses, and contractors must provide a detailed safety plan for handling potent substances. Selection is based on the highest combined rating of technical merit and price, with financial bid ceilings set at 120,000 CAD for Stream 1, 70,000 CAD for Stream 2, and 80,000 CAD for Stream 3.

General Info

Health Canada seeks pharmacological testing of novel psychoactive substances across three specific streams.

Agency

Government of Canada → Department of Health

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

National Capital Region (NCR), CAN

Set-Aside

NONE

Documents

1000273405 Request for Proposal – Pharmacological Testing of Synthetic Drugs

rfp

High

Annexe A - EDT Flux 1: Évaluation in vitro d'opioïdes émergents

sow

High

Annexe A - EDT Flux 1 - SOW

sow

High

Annexe B - EDT Flux 2 - Amendment 1

sow

High

Appendix A - SOW Stream 1 Amended: In vitro pharmacological testing of emerging opioids

sow

High

Appendix A - SOW Stream 1: In vitro pharmacological testing of emerging opioids

sow

High

Appendix B - SOW Stream 2 Amendment 1

amendment

High

Appendix C - Statement of Work: In vitro pharmacological testing

sow

High

Q&A #2 – Solicitation Update on Appendix A Table II and SOW Annex A

q-and-a

High

Qs & As #1 - RFP submission questions and answers

q-and-a

High

Questions and Answers #3

1 page · q-and-a

High

RFP 1000273405 - Pharmacological Testing for Novel Opioids, Stimulants, and Cannabinoids

rfp

High

Annexe C - EDT Flux 3-final

other

Low

AI Contract Breakdown

Uniform Contract Format

Timeline

1 update

PhaseClosed

PostedSep 1

Solicitation

Deadline changedSep 15

Response deadline changed from Sep 18, 2026 to Sep 25, 2026.

Response DeadlineSep 25

Deadline has passed

Submission Closed

09/25/2026, 05:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyGovernment of Canada → Department of Health

Contacts1 person available

OfficeN/A

Organization / AgencyGovernment of Canada → Department of Health

Office AddressN/A

Contacts

Shallee DollContracting Authority

contact@example.gov

Full Description

Request For Proposal (RFP) for Pharmacological testing of novel opioids, stimulants, and synthetic cannabinoids. Amendment 1 - Questions & Answers #1 and Amendment to Annex B - SOW Stream 2 Amendment 2 - Questions & Answers #2 and Amendment to Annex A - SOW Stream 1 Novel psychoactive substances (NPS) in the illegal drug supply pose risks to Canadians. However, little is known about their pharmacological activity. More potent drugs increase the risk of overdose risks. Evidence on the pharmacological activity of these substances is essential to support scientific regulatory activities and risk assessments. The illegal drug supply is continuously evolving, with new substances continually being detected. There is a need for further information on their harms to Canadians. This procurement activity will allow for the evaluation of the in vitro pharmacological activity of three categories of emerging drugs: novel synthetic opioids, synthetic cannabinoids, and stimulants. The data generated from this contract will inform future assessment activities and allow the Office of Legislative and Regulatory Affairs (OLRA) to make more informed regulatory science decisions. For all three streams, they require the pharmacological testing of different classes of substances, and require acquisition of reference standards and control samples, getting licenses for controlled substances, conducting experiments (including doing statistical analysis), and finally drafting and finalizing reports. Canada is seeking offers from Offerors to provide Pharmacological Testing for Novel Opioids, Stimulants, and Synthetic Cannabinoids in three (3) separate streams to Health Canada. Stream 1 - In vitro pharmacological testing of emerging opioids at the Mu Opioid Receptor (MOR). Stream 2 – In vitro pharmacological testing of novel synthetic cannabinoids and Stream 3 – In vitro pharmacological testing of stimulant compounds. Each stream will be evaluated separately, and bidders are to provide their submissions for one (1) stream, two (2) streams or all three (3) streams. Up to three (3) contracts may be awarded under this request for proposal.